PARFENOV, E.V.,
MUKAEVA, V.R.,
FARRAKHOV, R.G.,
PARFENOVA, L.V.,
LUKINA, E.S.,
DYAKONOV, G.S.,
VALIEV, R.Z.,
DANILKO, K.V. (2019) presencein the PEO coating pores was proven by the EIS. For the in vitro
tests, fibroblasts were used
-allylmaleopimarimide and MPA N-benzylcarboxamide against
test strains of Gram-negative and Gram-positive microorganisms
LATYPOVA, G.M.,
BYCHENKOVA, M.A.,
KATAYEV, V.A.,
PERFILOVA, V.N.,
TYURENKOV, I.N.,
MOKROUSOV, I.S.,
PROKOFIEV, I.I.,
SALIKHOV, SH.M.,
IKSANOVA, G.R. (2019) with the loading
test, adrenoreactivity
test, and maximum isometric loading
test; CHF markers adrenomedullin
) to the most modern ones (computer
tests and quizzes, Internet portals to maintain the transparency
GORDEEVA, A.V.,
SITDIKOVA, I.D.,
GALIMOVA, I.A.,
GUREVSKAYA, O.А.,
USMANOVA, I.N.,
DETOCHKINA, V.R. (2019) . The microbiological method using modern
test systems found an extremely diverse state of the microbiota of the oral
AKHMADIEV, N.S.,
AKHMETOVA, V.R.,
IBRAGIMOV, A.G.,
GALIMOVA, A.M.,
GALIMOVA, R.A.,
AGLETDINOV, E.F.,
KATAEV, V.A.,
KHAIRULLINA, V.R. (2019) . The
tested compound is comparable, in terms of its activity to the hepatoprotective drug SAM according
Bogliolo, M.,
Catucci, I.,
Caleca, L.,
Lasheras, S.V.,
Pujol, R.,
Kiiski, J.I.,
Muranen, T.A.,
Barnes, D.R.,
Dennis, J.,
Michailidou, K.,
Bolla, M.K.,
Leslie, G.,
Figlioli, G. (2019) , with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We
tested the three